That or significantly restructure the deal. Does anyone know if there is a breakup fee if ETE backs out. None of my research indicates a BF could be in play as I have not found any information one way or the other.
I will admit that at $6.00 KPTI could present a compelling spec thesis. I was fortunate enough to benefit from the November run-up last year, but unfortunate in that I took a small position late last week which I sold today so my gains from November evaporated in the last three days. On balance the price action here has been some of the craziest I've ever seen but will again consider a spec play in the $6.00 range. Would be nice to hear something re: Selnixor
At this rate you'll very likely get your target price (especially if the market continues to tank which I suspect it will). Key question is what is the catalyst to buy even at that price. I know the IBD is down over 30% in the past year but KPTI is down more than 30% just in the past week (on top of last years precipitous decline). Makes you wonder if their Selnixor trials are going as planned or if there is a problem there.